Increased incidence of brain metastases in ERCC1-negative NSCLC patients treated with adjuvant cisplatin-based chemotherapy

被引：0
|
作者：
Besse, B.
Massard, C.
Haddad, V.
Andre, F.
Dunant, A.
Pirker, R.
Olaussen, K. A.
Brambilla, E.
Fouret, P.
Soria, J.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Med Univ Vienna, Vienna, Austria
[3] Ctr Hosp Univ Albert Michallon, Grenoble, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7581
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
    Besse, B.
    Massard, C.
    Haddad, V.
    Andre, F.
    Dunant, A.
    Pirker, R.
    Olaussen, K. A.
    Brambilla, E.
    Fouret, P.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 575 - 581
  • [2] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso
    Elena Zanellato
    Martina Nucifora
    Renzo Boldorini
    Angelica Sonzogni
    Roberto Biffi
    Nicola Fazio
    Eraldo Bucci
    Ottavio Beretta
    Stefano Crippa
    Piercarlo Saletti
    Milo Frattini
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 159 - 165
  • [3] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    De Dosso, Sara
    Zanellato, Elena
    Nucifora, Martina
    Boldorini, Renzo
    Sonzogni, Angelica
    Biffi, Roberto
    Fazio, Nicola
    Bucci, Eraldo
    Beretta, Ottavio
    Crippa, Stefano
    Saletti, Piercarlo
    Frattini, Milo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 159 - 165
  • [4] INCIDENCE OF THROMBOEMBOLIC EVENTS IN PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY
    Fernandes, A. C.
    Meireles, S. R.
    Augusto, I.
    Aguas, L.
    Damasceno, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 525 - 526
  • [5] ERCC1 OVEREXPRESSION PREDICTS POOR PROGNOSIS IN PATIENTS WITH GASTRIC/GE JUNCTION ADENOCARCINOMA TREATED WITH ADJUVANT CISPLATIN-BASED CHEMOTHERAPY
    De Dosso, Sara
    Nucifora, Martina
    Zanellato, Elena
    Boldorini, Renzo
    Angelica, Sonzogni
    Fazio, Nicola
    Biffi, Roberto
    Bucci, Eraldo
    Luca, Mazzucchelli
    Frattini, Milo
    Saletti, Piercarlo
    ANNALS OF ONCOLOGY, 2012, 23 : 49 - 50
  • [6] GENE POLYMORPHISMS ANALYSIS BY PYROSEQUENCING IN NSCLC PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY
    Paris, I.
    Cappellini, G. C. Antonini
    Lauro, S.
    Bassanelli, M.
    Malaguti, P.
    Gentile, G.
    Borro, M.
    Simmaco, M.
    Marchetti, P.
    ANNALS OF ONCOLOGY, 2009, 20 : 41 - 41
  • [7] Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
    Geiger, Sandra
    Schlemmer, Marcus
    Heinemann, Volker
    Stemmler, Hans Joachim
    ANTI-CANCER DRUGS, 2010, 21 (09) : 799 - 804
  • [8] Aortic occlusion in patients treated with cisplatin-based chemotherapy
    Grenader, Tal
    Shavit, Linda
    Ospovat, Inna
    Gutfeld, Orit
    Peretz, Tamar
    MOUNT SINAI JOURNAL OF MEDICINE, 2006, 73 (05): : 810 - 812
  • [9] Clinical implication of ERCC1 overexpression in advanced biliary tract adenocarcinoma patients treated with cisplatin-based palliative chemotherapy
    Hwang, In Gyu
    Lee, Gyeong-Won
    Kang, Jung Hun
    Oh, Sung Yong
    Kwon, Hyuk-Chan
    Jun, Hyun Jung
    Lim, Ho Yeong
    Lee, Seungkoo
    Jang, Joung-Soon
    Lee, Sang-Jae
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [10] Frontline gemcitabine and cisplatin based chemotherapy in patients with NSCLC inoperable brain metastases.
    Quadvlieg, V
    Bosquee, L
    Gustin, M
    Barthelemy, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 645S - 645S
12345